WARMINSTER, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August… Read More
August 1, 2019 A Form 10-Q has been filed with the United States Securities and Exchange Commission. View this filing → Or click here to view all filings.
WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference… Read More
Recent Milestone Demonstrates Continued Progress Across Three Concurrent Studies of VAL-083 in Different Phases of GBM Progression VANCOUVER, British Columbia and MENLO PARK, Calif., July 31, 2019 /PRNewswire/ — DelMar Pharmaceuticals,… Read More
New Study Arm Provides Significant Opportunity for Multiple Applications of VAL-083 Treatment in GBM VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar”… Read More
